EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita



Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita



Clinical Immunology 129(3): 518-519



This review summarizes progress in preventing and treating severe malaria, which has been accompanied by advances in our understanding of the pathogenesis of severe malaria complications. New drugs such as intravenous artesunate and oral artemisinin combinations, with increased access to insecticide-treated bed nets, are improving outcomes and decreasing malaria deaths. Several groups are beginning to identify characteristics of parasite var genes associated with cerebral malaria.

(PDF emailed within 0-6 h: $19.90)

Accession: 023706992

Download citation: RISBibTeXText

PMID: 18848500

DOI: 10.1016/j.clim.2008.08.003



Related references

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. Journal Of The American Academy Of Dermatology. 36(2 Part 2): 331-335, 1997

Severe ocular involvement in a patient with epidermolysis bullosa acquisita. Journal of the American Academy of Dermatology 16(2 Pt 2): 439-443, 1987

Results of intravenous immunoglobulin therapy in ocular involvement in epidermolysis bullosa acquisita. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 1388, 2003

Intravenous immunoglobulin therapy in patients with epidermolysis bullosa acquisita refractory to conventional therapy. Journal of Investigative Dermatology 121(1): 1232, July, 2003

Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. Journal of Dermatological Treatment (): 1-5, 2016

Severe acral contractures and nail loss in a patient with mechano-bullous Epidermolysis bullosa acquisita. European Journal of Dermatology 20(4): 543-544, 2010

Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. Journal of the European Academy of Dermatology and Venereology 21(8): 1141-1142, 2007

Heavy and light chain isotypes of immunoglobulin in epidermolysis bullosa acquisita. Journal of Investigative Dermatology 95(3): 317-319, 1990

Absence of platelet aggregation activity in blister fluids from epidermolysis bullosa dystrophica and epidermolysis bullosa acquisita. Journal of Dermatological Science 1(6): 467-468, 1990

Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up. Journal of the European Academy of Dermatology and Venereology 26(9): 1074-1083, 2012

Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. British Journal of Dermatology 133(3): 467-471, 1995

Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures. Indian Journal of Dermatology 56(2): 224-227, 2011

Clinicopathological case 1: mucous membrane pemphigoid, epidermolysis bullosa acquisita and linear immunoglobulin A disease. Clinical and Experimental Dermatology 28(4): 461-462, 2003

Epidermolysis bullosa acquisita in a patient with psoriasis vulgaris. European Journal of Dermatology 25(5): 499-500, 2016

Crescentic glomerulonephritis in a patient with epidermolysis bullosa acquisita. Nephron 70(1): 120-120, 1995